Bionano Genomics, Inc. (NASDAQ:BNGO – Get Free Report)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $5.82, but opened at $5.70. Bionano Genomics shares last traded at $5.42, with a volume of 63,738 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, LADENBURG THALM/SH SH cut Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Friday, November 15th.
Check Out Our Latest Stock Report on BNGO
Bionano Genomics Trading Up 1.4 %
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. Carret Asset Management LLC boosted its position in shares of Bionano Genomics by 89.0% in the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after purchasing an additional 40,055 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Bionano Genomics during the 3rd quarter valued at $46,000. Finally, Geode Capital Management LLC lifted its stake in shares of Bionano Genomics by 47.3% during the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after buying an additional 283,639 shares in the last quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.
About Bionano Genomics
Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.
See Also
- Five stocks we like better than Bionano Genomics
- 3 Stocks to Consider Buying in October
- ASML: Strengths and Upside Remain Despite DeepSeek Worries
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Royal Caribbean Soars, But Smooth Sailing Isn’t Guaranteed
- Basic Materials Stocks Investing
- Kimberly-Clark: A Regal Opportunity in This Dividend King
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.